Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print      Mail a friend

Tuesday 10 December, 2019

Sensyne Health PLC

Board Changes

RNS Number : 3247W
Sensyne Health PLC
10 December 2019
 

 

 

Board Changes

 

Oxford, UK; 10 December 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, announces that Annalisa Jenkins and Andrew Gilbert stepped down from the Board of Sensyne yesterday. The Board has appointed Sir Bruce Keogh, Independent Non-Executive Director, as Interim Non-Executive Chair of the Board, effective immediately, whilst the search continues for an independent non-executive chair and additional independent non-executive directors.  Spencer Stuart have been appointed to undertake the search on behalf of the Company.

 

Sir Bruce Keogh is the Chair of Birmingham Women's and Children's NHS Foundation Trust. He previously served as NHS Medical Director and Director General in the Department of Health from November 2007 to March 2013. Following the 2012 health service reforms he was appointed National Medical Director of NHS England from April 2013 to January 2018. During a decade as the most senior doctor in the NHS he had responsibility for national clinical policy and strategy.

 

Prior to joining the Department of Health, he had a distinguished international career as a cardiac surgeon, having first been a consultant at the Hammersmith Hospital in London, then University Hospital Birmingham before becoming Professor of Cardiac Surgery at UCL and Director of Surgery at the Heart Hospital.

 

As a result of these changes, Mary Hardy has been appointed as Senior Independent Director and Chair of the Nomination Committee.

 

Bruce Keogh, Chairman of Sensyne Health, said: "The Board would like to thank Annalisa and Andrew for their important and valuable contributions to the Company. We are now in the process of bolstering our Board and look forward to updating the market in due course."

 

-ENDS-

 

For more information please contact:

 

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer


Lorimer Headley, Chief Financial Officer




Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

Dr Christopher Golden


James Steel


Oliver Jackson


 

 


Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma


Euan Brown




Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott


Sukaina Virji


Melissa Gardiner


[email protected]


 

 

 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOACKKDQABDKKBD

a d v e r t i s e m e n t